Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 18/20 | 1.00 |
| ▸ | RARG | P13631 | 18/20 | 1.00 |
| ▸ | RARA | P10276 | 14/20 | 1.00 |
| ▸ | RXRA | P19793 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177444 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL29836848 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL2307487 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9419009 | 0.95 | RARB (0.90) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL9418968 | 0.95 | RARB (0.90) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL5304297 | 0.92 | RARB (0.85) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL5304306 | 0.92 | RARB (0.85) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL12498687 | 0.92 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL5304300 | 0.92 | RARB (0.85) | RARBRARGRARARXRAKDM4E | |
| Tromethamine SCHEMBL27599878 | 0.91 | RARB (0.82) | RARBRARGRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-12514834-B2 | Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy | KYOTO UNIVERSITY (JP) | 2026-01-06 | — | — | US | claimed |
| EP-4574171-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | Kyoto University (JP) | 2025-06-25 | — | — | EP | claimed |
| US-20250170083-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | KYOTO UNIVERSITY (JP) | 2025-05-29 | — | — | US | claimed |
| US-12180509-B2 | Methods for reprograming non-pluripotent cells into pluripotent stem cells | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-12-31 | — | — | US | claimed |
| WO-2024090521-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | 国立大学法人京都大学 | 2024-05-02 | — | — | WO | claimed |
| EP-3384007-B1 | IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-03-27 | — | — | EP | claimed |
| EP-3019596-B1 | COMPOSITIONS AND METHODS FOR REPROGRAMING NON- PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | HONG GUAN LTD (CN) | 2023-07-05 | — | — | EP | claimed |
| US-20220389067-A1 | Methods of Treating Neurodegenerative Diseases Caused by G4C2 Expansion in C9ORF72 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-08 | — | — | US | claimed |
| US-20220296579-A1 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | CORNELL UNIVERSITY (US) | 2022-09-22 | — | — | US | claimed |
| WO-1999007418-A2 | STERILE BIOERODIBLE IMPLANT DEVICE WITH IMPROVED BIOCOMPATABILITY AND METHOD | ALLERGAN SALES, INC. (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0804194-A1 | METHOD OF PREVENTING PROLIFERATION OF RETINAL PIGMENT EPITHELIUM BY RETINOIC ACID RECEPTOR AGONISTS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1997-11-05 | — | — | EP | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| WO-1996023498-A1 | METHOD OF PREVENTING PROLIFERATION OF RETINAL PIGMENT EPITHELIUM BY RETINOIC ACID RECEPTOR AGONISTS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1996-08-08 | — | — | WO | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| EP-0263492-B1 | RETINOIDS, THEIR PREPARATION AND USE AS PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 1991-03-13 | — | — | EP | claimed |
| US-4900478-A | SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-02-13 | — | — | US | claimed |
| US-4877805-A | REVERSING COLLAGEN FIBER LOSS BY APPLYING TO FACE | KLIGMAN ALBERT M (US) | 1989-10-31 | — | — | US | claimed |
| US-4326055-A | ANTITUMOR AGENTS, SKIN DISORDERS, RHEUMATIC DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1982-04-20 | — | — | US | claimed |
| EP-0002742-B1 | STILBENE DERIVATIVES, THEIR PREPARATION AND MEDICINES CONTAINING THESE STILBENE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-04-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296579-A1 | COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS | RARB, RARG, RARA | RARB 1/4885RARG 2/4885RARA 3/4885 |
| US-12180509-B2 | Methods for reprograming non-pluripotent cells into pluripotent stem cells | AHCY, BHMT, SHMT1 | RARB 294/4885RARG 358/4885RARA 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.